Record Sales and Growth
Globus Medical reported exceptional third-quarter sales of $626 million, growing 63% or $242 million. Non-GAAP EPS was a record $0.83, increasing 45% even with a 20% increase in diluted shares versus the prior year.
Successful Product Launches
Globus launched 4 new products in Q3, reaching 13 product launches year-to-date, with plans for more by the end of the year. These innovations include the Excelsius Navigation hub and the ACTIFY 3D Total Knee System.
Strong International and Musculoskeletal Revenue
International spinal implant business delivered record sales in Q3, growing 86% on a constant currency basis. Musculoskeletal revenue was $587.4 million, growing 65% compared to the prior year.
Enabling Technology Sales Growth
Enabling Technology sales were $38 million, an increase of 39% versus prior year. Q3 was the highest number of unit placements since launch, growing 50% over prior Q3.
Record Free Cash Flow
Record free cash flow of $162 million in Q3, equivalent to the 2023 full year free cash flow.
Increased Guidance for 2024
Globus Medical increased its guidance, expecting 2024 net sales to be in the range of $2.49 billion to $2.5 billion, with revised non-GAAP EPS expected to be in the range of $2.90 to $3 per fully diluted share.